CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Standard Medical TreatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1248 Intravenous Immune Globulin Wiki 1.00
drug2801 diagnostic Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19

The purpose of the study is to determine if high dose Intravenous IVIG plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical ventilation on Day 29 versus SMT alone in hospitalized participants with COVID-19.

NCT04432324 COVID-19 Biological: Intravenous Immune Globulin Drug: Standard Medical Treatment
MeSH:Coronavirus Infections

Primary Outcomes

Measure: Percentage of Participants Dying or Requiring ICU Admission

Time: Up to Day 29

Measure: Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation

Time: Day 29

Secondary Outcomes

Measure: Change from Baseline in National Early Warning Score (NEWS)

Time: Day 1 through Day 29

Measure: Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours

Time: Day 1 through Day 29

Measure: Time to Hospital Discharge

Time: Day 1 through Day 29

Measure: Duration of ICU Stay

Time: Up to Day 29

Measure: Duration of Any Oxygen Use

Time: Day 1 through Day 29

Measure: Duration of Mechanical Ventilation

Time: Up to Day 29

Measure: Absolute Value and Mean Change from Baseline in Ordinal Scale

Time: Day 1 through Day 29

Measure: Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale

Time: Day 15 and Day 29

Measure: Time to Sustained Normalization of Temperature

Time: Day 1 through Day 29

Measure: Percentage of Participants with Normalization of Fever

Time: Day 1 through Day 29

Measure: Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)

Time: Day 29

Measure: Length of Time to Clinical Progression

Time: Up to Day 29

No related HPO nodes (Using clinical trials)